Oxime K027: novel low-toxic candidate for the universal reactivator of nerve agent- and pesticide-inhibited acetylcholinesterase

References

• Kuca K, Bielavsky J, Cabal J, Bielavska M. Synthesis of a potential reactivator of acetylcholinesterase 1-(4-hydroxyiminomethylpyridinium)-3-(carbamoylpyridinium)-propane dibromide. Tetrahedron Lett 2003;44:3123–5.
   Web of Science ®Google Scholar
• Kassa J, Kuca K, Bartosova L, Kunesova G. The development of new structural analogues of oximes for the antidotal treatment of poisoning by nerve agents and the comparison of their reactivating and therapeutic efficacy with currently available oximes. Curr Org Chem 2007;11:267–83.
   Web of Science ®Google Scholar
• Kuca K, Kassa J. In vitro reactivation of acetylcholinesterase using of the oxime K027. Vet Hum Toxicol 2004;46:15–18.
   PubMedGoogle Scholar
• Kuca K, Kassa J. Oximes-induced reactivation of rat brain acetylcholinesterase inhibited by VX agent. Hum Exp Toxicol 2004;23:167–71.
   PubMed Web of Science ®Google Scholar
• Kuca K, Bartosova L, Kassa J, Cabal J, Bajgar J, Kunesova G, et al. Comparison of the potency of newly developed and currently available oximes to reactivate nerve agent-inhibited acetylcholinesterase in vitro and in vivo. Chem Biol Interact 2005;157–8:367–8.
   PubMed Web of Science ®Google Scholar
• Kuca K, Cabal J, Bajgar J, Jun D. In vitro searching for a new potent reactivator of acetylcholinesterase inhibited by nerve agent VX. Lett Drug Des Discov 2005;2:23–5.
   Web of Science ®Google Scholar
• Kuca K, Cabal J. Evaluation of newly synthesized reactivators of the brain cholinesterase inhibited by sarin-nerve agent. Toxicol Mech Methods 2005;15:247–52.
   PubMed Web of Science ®Google Scholar
• Kuca K, Cabal J, Kassa J. A comparison of the potency of newly developed oximes (K005, K027, K033, K048) and currently used oximes (pralidoxime, obidoxime, HI-6) to reactivate sarin-inhibited rat brain acetylcholinesterase by in vitro methods. J Toxicol Environ Health A 2005;68:677–86.
   PubMed Web of Science ®Google Scholar
• Kuca K, Cabal J, Jun D, Bajgar J, Hrabinova H. Potency of new structurally different oximes to reactivate cyclosarin inhibited-human brain acetylcholinesterases. J Enzyme Inhib Med Chem 2006;21:663–6.
   PubMed Web of Science ®Google Scholar
• Kuca K, Jun D, Cabal J, Musilova L. The bisquaternary oximes as reactivators of tabun-inhibited human brain cholinesterases – in vitro study. Basic Clin Pharmacol Toxicol 2007;101:25–8.
   PubMed Web of Science ®Google Scholar
• Berend S, Lucic-Vrdoljak A, Radic B, Kuca K. New bispyridinium oximes: in vitro evaluation of their biochemical parameters. Chem Biol Interact 2008;175:413–16.
   PubMed Web of Science ®Google Scholar
• Musilek K, Jun D, Cabal J, Kassa J, Gunn-Moore F, Kuca K. Design of a potent reactivator of tabun-inhibited acetylcholinesterase – synthesis and evaluation of (E)-1-(4-carbamoylpyridinium)-4-(4-hydroxyiminomethylpyridinium)-but-2-ene dibromide (K203). J Med Chem 2007;50:5514–18.
   PubMed Web of Science ®Google Scholar
• Kassa J. The influence of oxime and anticholinergic drug selection on the potency of antidotal treatment to counteract acute toxic effects of tabun in mice. Neurotox Res 2006;9:59–62.
   PubMed Web of Science ®Google Scholar
• Kassa J, Kunesova G. A comparison of the potency of newly developed oximes (K027, K048) and commonly used oximes (obidoxime, HI-6) to counteract tabun-induced neurotoxicity in rats. J Appl Toxicol 2006;26:309–16.
   PubMed Web of Science ®Google Scholar
• Kassa J, Kunesova G. The influence of antidotal treatment of low-level tabun exposure on cognitive functions in rats using a water maze. Neurotox Res 2006;9:39–45.
   PubMed Web of Science ®Google Scholar
• Kassa J, Kuca K, Cabal J, Paar M. A comparison of the efficacy of new asymmetric bispyridinium oximes (K027, K048) with currently available oximes against tabun by in vitro and in vivo methods. J Toxicol Environ Health 2006;69:1875–82.
   PubMed Web of Science ®Google Scholar
• Kassa J, Kuca K, Karasova J, Musilek K. The development of new oximes and the evaluation of their reactivating, therapeutic and neuroprotective efficacy against tabun. Mini Rev Med Chem 2008;8:1134–43.
   PubMed Web of Science ®Google Scholar
• Calic M, Lucic-Vrdoljak A, Radic B, Jelic D, Jun D, Kuca K, et al. In vitro and in vivo evaluation of pyridinium oximes: mode of interaction with acetylcholinesterase, effect on tabun- and soman-poisoned mice and their cytotoxicity. Toxicology 2006;219:85–96.
   PubMed Web of Science ®Google Scholar
• da Silva AP, Farina M, Franco JL, Dafre AL, Kassa J, Kuca K. Temporal effects of newly developed oximes (K027, K048) on malathion-induced acetylcholinesterase inhibition and lipid peroxidation in mouse prefrontal cortex. Neurotoxicology 2008;29:184–9.
   PubMed Web of Science ®Google Scholar
• Lucic-Vrdoljak A, Calic M, Radic B, Berend S, Kuca K, Kovarik Z. Pre-treatment with pyridinium oximes improves antidotal therapy against tabun poisoning. Toxicology 2006;228:41–50.
   PubMed Web of Science ®Google Scholar
• Pejchal J, Osterreicher J, Kuca K, Jun D, Bajgar J, Kassa J. Possible hepatotoxicity of acetylcholinesterase reactivators – nerve agent antidotes. Basic Clin Pharmacol Toxicol 2008;103:119–23.
   PubMed Web of Science ®Google Scholar
• Gyenge M, Kalasz H, Petroianu G, Laufer R, Kuca K, Tekes K. Measurement of K-27, an oxime-type cholinesterase reactivator by high performance liquid chromatography with electrochemical detection from different biological samples. J Chromatogr A 2007;1161:146–51.
   PubMed Web of Science ®Google Scholar
• Tekes K, Hasan MY, Sheen R, Kuca K, Petroianu G, Ludanyi K, et al. HPLC determination of the serum concentration of K-27, a novel oxime-type cholinesterase reactivator. J Chromatogr A 2006;1122:84–7.
   PubMed Web of Science ®Google Scholar
• Lorke DE, Kalasz H, Petroianu GA, Tekes K. Entry of oximes into the brain: a review. Curr Med Chem 2008;15:743–53.
   PubMed Web of Science ®Google Scholar
• Lorke DE, Hasan MY, Arafat K, Kuca K, Musilek K, Schmitt A, et al. In vitro oxime protection of human red blood cell acetylcholinesterase inhibited by diisopropyl-fluorophosphate. J Appl Toxicol 2008;28:422–9.
   PubMed Web of Science ®Google Scholar
• Lorke DE, Hasan MY, Nurulain SM, Sheen R, Kuca K, Petroianu GA. Entry of two new asymmetric bispyridinium oximes (K-27 and K-48) into the brain: comparison with obidoxime. J Appl Toxicol 2007;27:482–90.
   PubMed Web of Science ®Google Scholar
• Lorke DE, Nurulain SM, Hasan MY, Kuca K, Musilek K, Petroianu GA. Eight new bispyridinium oximes in comparison with the conventional oximes pralidoxime and obidoxime: in vivo efficacy to protect from diisopropylfluorophosphate (DFP) toxicity. J Appl Toxicol 2008;28:920–8.
   PubMed Web of Science ®Google Scholar
• Lorke DE, Hasan MY, Nurulain SM, Kuca K, Schmitt A, Petroianu GA. Efficacy of two new asymmetric bispyridinium oximes (K-27 and K-48) in rats exposed to diisopropylfluorophosphate: comparison with pralidoxime, obidoxime, trimedoxime, methoxime, and HI-6. Toxicol Mech Methods 2009;19:327–33.
   PubMed Web of Science ®Google Scholar
• Nurulain SM, Lorke DE, Hasan MY, Shafiullah M, Kuca K, Musilek K, et al. Efficacy of eight experimental bispyridinium oximes against paraoxon-induced mortality: comparison with the conventional oximes pralidoxime and obidoxime. Neurotox Res 2009;16:60–7.
   PubMed Web of Science ®Google Scholar
• Petroianu GA, Arafat K, Nurulain SM, Kuca K, Kassa J. In vitro oxime reactivation of red blood cell acetylcholinesterase inhibitied by methyl-paraoxon. J Appl Toxicol 2007;27:168–75.
   PubMed Web of Science ®Google Scholar
• Petroianu GA, Lorke DE. Pyridinium oxime reactivators of cholinesterase inhibited by diisopropyl-fluorophosphate (DFP): predictive value of in-vitro testing for in-vivo efficacy. Mini Rev Med Chem 2008;8:1328–42.
   PubMed Web of Science ®Google Scholar
• Petroianu GA, Arafat K, Kuca K, Kassa J. Five oximes (K-27, K-33, K-48, BI-6 and methoxime) in comparison with pralidoxime: in vitro reactivation of red blood cell acetylcholinesterase inhibitied by paraoxon. J Appl Toxicol 2006;26:64–71.
   PubMed Web of Science ®Google Scholar
• Petroianu GA, Hasan MY, Nurulain SM, Nagelkerke N, Kassa J, Kuca K. New K-oximes (K-27and K-48) in comparison with obidoxime (LuH-6), HI-6, trimedoxime (TMB-4) and pralidoxime (2-PAM): survival in rats exposed ip to the organophosphate paraoxon. Toxicol Mech Methods 2007;17:401–8.
   PubMed Web of Science ®Google Scholar
• Petroianu GA, Nurulain SM, Nagelkerke N, Al-Sultan MAH, Kuca K, Kassa J. Five oximes (K-27, K-33, K-48, BI-6 and methoxime) in comparison with pralidoxime: survival in rats exposed to the organophosphate paraoxon. J Appl Toxicol 2006;26:262–8.
   PubMed Web of Science ®Google Scholar
• Petroianu GA, Nurulain SM, Nagelkerke N, Shafiullah M, Kassa J, Kuca K. Five oximes (K-27, K-48, obidoxime, HI-6 and trimedoxime) in comparison with pralidoxime: survival in rats exposed to methyl-paraoxon. J Appl Toxicol 2007;27:453–7.
   PubMed Web of Science ®Google Scholar
• Park NJ, Jung YS, Musilek K, Jun D, Kuca K. Potency of several structurally different acetylcholinesterase reactivators to reactivate house fly and bovine acetylcholinesterase inhibited by paraoxon and DFP. Bull Korean Chem Soc 2006;27:1401–9.
   Web of Science ®Google Scholar
• Jun D, Stodulka P, Kuca K, Koleckar V, Dolezal B, Simon P, et al. TLC analysis of intermediates arising during the preparation of oxime HI-6 dimethanesulfonate. J Chromatogr Sci 2008;46:316–19.
   PubMed Web of Science ®Google Scholar
• Musilek K, Lipka L, Racakova V, Kuca K, Jun D, Dohnal V, et al. New methods in synthesis of acetylcholinesterase reactivators and evaluation of their potency to reactivate cyclosarin-inhibited AChE. Chem Pap 2006;60:48–51.
   Web of Science ®Google Scholar
• Novotny L, Karasova J, Kuca K, Bajgar J, Misik J. Influence of different ways of euthanasisa on the activity of cholinesterases in the rat. J Appl Biomed 2009;7:115–18.
   Web of Science ®Google Scholar
• Kuca K, Musilek K, Jun D, Pohanka M, Zdarova Karasova J, Novotny L, Musilova L. Could oxime HI-6 really be considered as “broad-spectrum” antidote?. J Appl Biomed 2009;7,143–149.
   Web of Science ®Google Scholar
• Bajgar J, Fusek J, Kuca K, Bartosova L, Jun D. Treatment of organophosphate intoxication using cholinesterase reactivators: facts and fiction. Mini Rev Med Chem 2007;7:461–6.
   PubMed Web of Science ®Google Scholar
• Musilek K, Holas O, Kuca K, Jun D, Dohnal V, Opletalova V, et al. Synthesis of monooxime-monocarbamoyl bispyridinium compounds bearing (E)-but-2-ene linker and evaluation of their reactivation activity against tabun- and paraoxon-inhibited acetylcholinesterase. J Enzyme Inhib Med Chem 2007;23:70–6.
   Web of Science ®Google Scholar
• Pohanka M, Jun D, Kuca K. Photometric microplate assay for estimation of the efficacy of paraoxon-inhibited acetylcholinesterase reactivation. J Enzyme Inhib Med Chem 2008;23:781–4.
   PubMed Web of Science ®Google Scholar
• Pohanka M, Jun D, Kuca K. In vitro reactivation of trichlorfon-inhibited butyrylcholinesterase using HI-6, obidoxime, pralidoxime and K048. J Enzyme Inhib Med Chem 2009;24:680–3.
   PubMed Web of Science ®Google Scholar
• Kassa K, Karasova J, Bajgar J, Kuca K, Musilek K. A comparison of the therapeutic and reactivating efficacy of newly developed bispyridinium compounds (K206, K269) with currently available oximes against tabun in rats and mice. J Enzyme Inhib Med Chem 2008;23:776–80.
   PubMed Web of Science ®Google Scholar
• Kassa J, Karasova J, Bajgar J, Kuca K, Musilek K, Kopelikova I. A comparison of the reactivating and therapeutic efficacy of newly developed bispyridinium oximes (K250, K251) with commonly used oximes against tabun in rats and mice. J Enzyme Inhib Med Chem 2009;24:1040–4.
   PubMed Web of Science ®Google Scholar